Pharma Focus Asia

LG Chem and AVEO Oncology Have Announced the Commencement of Phase 1 Clinical Trials for LG Chem's Inaugural Proprietary Anti-cancer Compound, With Dosing Initiated in the United States

Friday, June 14, 2024

LG Chem, in partnership with its subsidiary AVEO Oncology, has commenced the initial patient enrollment in the United States for a Phase 1 clinical trial of LB-LR1109 (NCT06332755; LG project code LR19155), marking LG Chem's debut proprietary anti-cancer drug candidate. This collaboration aims to develop effective strategies for the drug's advanced clinical development and regulatory approval.

This Phase 1 trial is a multi-center, open-label, non-randomized dose escalation study designed to establish the appropriate dose for Phase 2 trials. It will also evaluate the safety, tolerability, preliminary efficacy, pharmacokinetics, immunogenicity, and pharmacodynamics of LB-LR1109, and its impact on the quality of life for patients with unresectable and metastatic cancers, including non-small cell lung cancer, head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma, or malignant melanoma, who have not responded to standard treatments.

In preclinical studies, LB-LR1109 has shown dose-dependent anti-cancer activity, and it received approval from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug application in the previous December.

Leukocyte immunoglobulin-like receptor B-1 (LILRB1), a protein produced by cancer cells to avoid immune attack, is commonly present on various immune cells such as T cells, natural killer cells, and macrophages. LB-LR1109 is designed to activate these immune cells simultaneously, which may provide a distinct approach compared to therapies that focus on single types of immune cells.

"We are excited to work with LG Chem on their innovative anti-cancer drug," said Dr. Alex Spira, Director of Next Oncology at Virginia Cancer Specialists Research Institute and head of the Phase 1 Trial Program. "There is a critical need for new treatments for patients who have progressed beyond standard therapies, highlighting the importance of exploring new immune checkpoint inhibitors like LB-LR1109."

LG Chem Life Sciences Company, noted, "We are dedicating all our resources to develop groundbreaking treatments that will be valuable to both medical professionals and patients. As LG Chem's first oncology drug, this project is just the beginning of our efforts to create a strong pipeline of innovative oncology therapies. We are committed to providing unique treatment options in oncology, a field with significant unmet needs."

Advancing LB-LR1109 into clinical trials brings LG Chem and AVEO Oncology closer to their goal of becoming leaders in oncology with a diverse pipeline of innovative therapies.



magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference